Sugammadex 2 mg/kg + Sugammadex 4 mg/kg + Neostigmine + Glycopyrrolate + Neostigmine + Atropine
ApprovedCompleted 0 watching 0 views this week๐ฅ Hot
85
Development Stage
โ
Pre-clinicalโ
Phase 1โ
Phase 2โ
Phase 35
ApprovedIndication / Disease
Neuromuscular Blockade
Conditions
Neuromuscular Blockade
Trial Timeline
Feb 12, 2018 โ Jan 28, 2020
NCT ID
NCT03351608About Sugammadex 2 mg/kg + Sugammadex 4 mg/kg + Neostigmine + Glycopyrrolate + Neostigmine + Atropine
Sugammadex 2 mg/kg + Sugammadex 4 mg/kg + Neostigmine + Glycopyrrolate + Neostigmine + Atropine is a approved stage product being developed by Merck for Neuromuscular Blockade. The current trial status is completed. This product is registered under clinical trial identifier NCT03351608. Target conditions include Neuromuscular Blockade.
Hype Score Breakdown
Clinical
30
Activity
20
Company
10
Novelty
10
Community
12
Clinical Trials (2)
| NCT ID | Phase | Status |
|---|---|---|
| NCT03909165 | Approved | Completed |
| NCT03351608 | Approved | Completed |
Competing Products
20 competing products in Neuromuscular Blockade